CoreRx, Inc. a Contract Development Manufacturing Organization (CDMO) with a focus on clinical phase drug product development, plans to continue expansion of its drug product development and manufacturing capabilities in Clearwater, Florida.
This new build-out comes on the heels of CoreRx nearing completion of its previous growth efforts to its first building in the ICOT center campus. This build out consisted of 5 new manufacturing suites, and also added large scale capacity to its Wet Granulation/Fluid Bed Processing operations.
The expansion will take place in the ICOT center campus in a third building which will include 15,000 square feet of space for a new warehouse, offices, and additional manufacturing which includes suites that can support GMP requirements for international clinical studies.
"This is an exciting time for CoreRx, but our growth has presented real challenges with regard to space within our previous existing facilities, both to accommodate the new equipment required to manufacture an ever-expanding range of products, and the numerous people that we are currently recruiting for all aspects of our business," said Todd R. Daviau, President/CEO. "The new site acquisition and proposed additions to our operations are a necessary part of ensuring for the longer term that we can continue to prosper and create high quality jobs in the area."
According to company officials, with the new expansion, CoreRx's clients now have access to over 120,000 square feet of space at the ICOT center campus. The additional expansions should be completed by the middle of Q2 2017, and will include 35 additional employees its Clearwater workforce over time.